Human recombinant cranulocyte-macrophage colony-stimulating factor in pediatric oncology practice

Thomas Ferencz, Csilla Csaki, Dezso Schuler, Joseph D. Borsi

Research output: Contribution to journalArticle

5 Citations (Scopus)


This paper reports preliminary experiences with human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with malignant diseases administered for three indications: (1) chemotherapy-induced neutropenia and sepsis, (2) prolonged neutropenia decreasing dose intensity, and (3) prevention of neutropenia after sublethal doses of chemotherapy.It was concluded that in the doily dose of S μg/kg subcutaneously, GM-CSF is capable of reducing the duration of chemotherapy-induced neutropenia and may be an effective tool in maintaining dose intensity and achieving dose escalation.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalPediatric hematology and oncology
Issue number2
Publication statusPublished - Jan 1 1994


  • Human recombinant granulocyte-macrophage colony-stimulating factor
  • Neutropenia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Human recombinant cranulocyte-macrophage colony-stimulating factor in pediatric oncology practice'. Together they form a unique fingerprint.

  • Cite this